

1 November 2012 | 13 pages

Electric Utilities (GICS) | Electric Utilities (Citi)

Asia Pacific | India

Power Grid Corporation of India (PGRD.BO)

Delivers A Solid Set Of Numbers Again


- Significant recurring PAT beat PGCIL's 2QFY13 recurring PAT at Rs11.1bn was up 57% YoY which was 28% ahead of Citi at Rs8.7bn. (For investors who like to adjust FERV and look at the numbers, adjusted PAT at Rs10.2bn up 31% YoY was also significantly ahead of expectations). 1HFY13 recurring PAT at Rs19.8bn is up 40% YoY, which could suggest upside risk to our FY13E estimates.
- Operationally robust Cash flow from operations (CFO) at Rs45bn v/s reported PAT of Rs19.9bn suggests improvement in working capital in 1HFY13. Capitalization in 1HFY13 at Rs67.7bn is up 67% YoY and appears on track to meet Citi FY13E expectations of Rs120bn. Capex in 1HFY13 at Rs71bn is behind Citi FY13E expectations of Rs165bn, but we expect improvements in 2HFY13E.
- Does PGCIL plan to raise equity? If PGCIL does Rs1000bn in the XIIth plan there might be a marginal equity shortfall in FY13E/14E. But in these years the company may do capex at leverage > 70:30 and make up for the same over FY15E-17E. From FY15E onwards there is no mismatch, in our view. There is a regulatory cap of 75:25 and we believe PGCIL does not want to fully utilize this leeway.
- Does Government of India (GoI) plan to sell down stake? GoI has discussed this with PGCIL, but we understand that management has asked that GoI not sell down its stake. The GoI stake is not that large and it could become tricky if it sells down its stake now and 5 years later PGCIL needs to raise equity for growth.
- Ministry of Power also does not want stake sell down According to the Hindustan Times, in a letter to the finance minister the outgoing power minister said that disinvestment in PGCIL has already taken place twice. Any further disinvestment in PGCIL may be deferred by GoI as this could be detrimental to the company's growth.
- **Top India Electric Utility pick** PGCIL continues to be our top pick along with JP Power (JAPR.BO; Rs38.40; 1). Our top sells are Tata Power (TTPW.BO; Rs105.50; 3) and Adani Power (ADAN.BO; Rs48.80; 3).

Company Update

Buy	1
Price (31 Oct 12)	Rs114.05
Target price	Rs140.00
Expected share price return	22.8%
Expected dividend yield	2.0%
Expected total return	24.8%
Market Cap	Rs528,020M
	US\$9,814M

Price Performance

(RIC: PGRD.BO, BB: PWGR IN)



Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2011A	25,437	5.49	11.9	20.8	2.5	13.6	1.5
2012A	32,710	7.07	28.6	16.1	2.2	14.6	1.9
2013E	39,092	8.44	19.5	13.5	2.0	15.7	2.0
2014E	45,143	9.75	15.5	11.7	1.8	16.3	2.1
2015E	51,624	11.15	14.4	10.2	1.6	16.5	2.2

Venkatesh Balasubramaniam +91-22-6631-9864

venkatesh.balasubramaniam@citi.com

Atul Tiwari, CFA atul.tiwari@citi.com

Deepal Delivala deepal.delivala@citi.com

Vaishnavi G vaishnavi.g@citi.com

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

PGRD.BO: Fiscal year end	31-Mar					Price: Rs114.05;	TP: Rs140.00;	Market Cap	o: Rs528,0	20m; Reco	mm: Buy
Profit & Loss (Rsm)	2011	2012	2013E	2014E	2015E	Valuation ratios	2011	2012	2013E	2014E	2015
Sales revenue	81,862	100,353	124,172	144,160	162,609	PE (x)	20.8	16.1	13.5	11.7	10.
Cost of sales	-13,420	-15,396	-17,831	-20,364	-23,274	PB (x)	2.5	2.2	2.0	1.8	1.
Gross profit	68,442	84,958	106,341	123,796	139,336	EV/EBITDA (x)	12.2	10.8	9.7	9.0	8.
Gross Margin (%)	83.6	84.7	85.6	85.9	85.7	FCF yield (%)	-16.7	-24.3	-16.0	-13.0	-10.
EBITDA (Adj)	68,442	84,958	106,341	123,796	139,336	Dividend yield (%)	1.5	1.9	2.0	2.1	2.5
EBITDA Margin (Adj) (%)	83.6	84.7	85.6	85.9	85.7	Payout ratio (%)	32	30	27	25	22
Depreciation	-21,994	-25,725	-31,390	-36,593	-41,343	ROE (%)	14.5	14.5	15.7	16.3	16.
Amortisation	0	0	0	0	0	Cashflow (Rsm)	2011	2012	2013E	2014E	2015E
EBIT (Adj)	46,448	59,232	74,951	87,203	97,993	EBITDA	68,442	84,958	106,341	123,796	139,336
EBIT Margin (Adj) (%)	56.7	59.0	60.4	60.5	60.3	Working capital	-34,718	-15,779	5,212	4,178	3,772
Net interest	-17,282	-20,567	-26,771	-30,908	-34,333	Other	-15,422	-22,464	-30,859	-36,560	-41,369
Associates	0	0	0	0	0	Operating cashflow	18,302	46,714	80,694	91,415	101,738
Non-op/Except	7,101	7,497	7,604	7,779	7,971	Capex	-106,529	-174,815	-165,000	-160,000	-155,000
Pre-tax profit	36,266	46,163	55,785	64,074	71,631	Net acq/disposals	0	0	0	0	(
Tax	-10,830	-13,452	-16,693	-18,930	-20,007	Other	549	1,139	1,495	1,495	1,49
Extraord./Min.Int./Pref.div.	1,532	-161	0	0	0	Investing cashflow	-105,980	-173,676	-163,505	-158,505	-153,50
Reported net profit	26,969	32,550	39,092	45,143	51,624	Dividends paid	-9,426	-11,339	-12,359	-12,897	-13,434
Net Margin (%)	32.9	32.4	31.5	31.3	31.7	Financing cashflow	91,702	113,530	83,439	71,009	51,371
Core NPAT	25,437	32,710	39,092	45,143		Net change in cash	4,024	-13,432	629	3,918	-390
Per share data	2011	2012	2013E	2014E	2015E	=	rs -88,227	-128,101	-84,306	-68,585	-53,262
Reported EPS (Rs)	5.83	7.03	8.44	9.75	11.15		•	•	,		•
Core EPS (Rs)	5.49	7.07	8.44	9.75	11.15						
DPS (Rs)	1.75	2.11	2.30	2.40	2.50						
CFPS (Rs)	3.95	10.09	17.43	19.75	21.98						
FCFPS (Rs)	-19.06	-27.67	-18.21	-14.81	-11.50						
BVPS (Rs)	46.15	50.73	56.51	63.47	71.72						
Wtd avg ord shares (m)	4,630	4,630	4,630	4,630	4,630						
Wtd avg diluted shares (m)	4,630	4,630	4,630	4,630	4,630						
Growth rates	2011	2012	2013E	2014E	2015E						
Sales revenue (%)	14.9	22.6	23.7	16.1	12.8						
EBIT (Adj) (%)	18.7	27.5	26.5	16.3	12.4						
Core NPAT (%)	23.0	28.6	19.5	15.5	14.4						
Core EPS (%)	11.9	28.6	19.5	15.5	14.4						
Balance Sheet (Rsm)	2011	2012	2013E	2014E	2015E						
Cash & cash equiv.	36,801	23,369	23,997	27,916	27,520						
Accounts receivables	31,621	28,463	35,219	40,888	46,121						
Inventory	3,815	4,403	5,448	6,325	7,135						
Net fixed & other tangibles	609,369	758,458		1,015,475							
Goodwill & intangibles	0	0	0	0	0						
Financial & other assets	75,610	107,468	107,973	108,478	108,983						
Total assets	757,216		1,064,705	1,199,081	1,318,890						
Accounts payable	18,368	0	0	0	0						
Short-term debt	0	0	0	0	0						
Long-term debt	408,828	534,019	629,918	713,923	778,828						
Provisions & other liab	116,350	153,264	173,177	191,301	208,016						
Total liabilities	543,546	687,283	803,095	905,225	986,844						
Shareholders' equity	213,670	234,878	261,610	293,857	332,046						
Minority interests	0	0	0	0	0						
Total equity	213,670	234,878	261,610	293,857	332,046						
Net debt	372,027	510,650	605,920	686,008	751,308						

For further data queries on Citi's full coverage universe please contact Citi Research Data Services at CitiRsch.DataServices.Global@citi.com For definitions of the items in this table, please click <a href="https://pere.



Figure 1. PGCIL: 2QFY13 Results Review

Year End Mar 31 (Rsmn)	1QFY12R	1QFY13	Growth	2QFY12R	2QFY13	Growth	2QFY13E
Transmission Assets CoD	8,020	40,730	407.9%	32,550	27,030	-17.0%	
Сарех	19,430	30,070		NA	40,930		
Sales	22,025	28,883	31.1%	22,644	30,858	36.3%	29,518
EBITDA	18,199	24,646	35.4%	18,699	26,693	42.8%	24,795
Margins %	82.6%	85.3%		82.6%	86.5%		84.0%
Depreciation	5,790	7,565		5,966	8,252		7,750
ЕВІТ	12,409	17,081	37.7%	12,732	18,441	44.8%	17,045
- Interest & Other Charges	4,190	6,101		4,593	6,343		
- FERV as adjustment in borrowing cost	(43)	360		683	(1,048)		
Total Interest and Finance Charges	4,148	6,461		5,277	5,296		6,500
Total Other Income	1,390	920		1,942	1,570		1,000
РВТ	9,651	11,540	19.6%	9,398	14,715	56.6%	11,545
Total Tax	2,586	2,836		2,331	3,597		2,840
Effective Tax Rate %	26.8%	24.6%		24.8%	24.4%		24.6%
Recurring PAT	7,065	8,705	23.2%	7,066	11,119	57.4%	8,705
Prior Period - Others	(13)	(4)		21	140		0
Reported PAT	7,053	8,701	23.4%	7,087	11,259	58.9%	8,705
PAT ex FERV according CIR calculated	7,010	9,061	29.3%	7,771	10,211	31.4%	8,705

Source: Company data, Citi Research estimates.

Figure	2.	PGC	IL 1H	IFY1	3 CFO
--------	----	-----	-------	------	-------

Year End Mar31 (Rsmn)	1HFY13
PAT	19,960
Depreciation	15,817
AAD	(367)
DTL	1,483
WC	8,345
CFO	45,238

Source: Company data, Citi Research.

Figure 3. PGCIL 2QFY13 Segmental Results Review

Rsmn	1QFY12R	1QFY13	Growth	2QFY12R	2QFY13	Growth
Revenues						
Transmission	21,776	28,166	29.3%	22,147	30,403	37.3%
Consultancy	543	612	12.7%	728	678	-6.9%
Telecom	462	571	23.7%	510	611	19.8%
Total Income	22,781	29,349	28.8%	23,385	31,692	35.5%
- Less Intersegment	(7)	(277)		(7)	(29)	
Net Sales	22,774	29,072	27.7%	23,377	31,663	35.4%
PBIT						
Transmission	12,767	17,018	33.3%	12,989	18,802	44.7%
Consultancy	210	321	53.1%	329	401	21.8%
Telecom	126	177	40.5%	169	183	8.6%
Total	13,103	17,517	33.7%	13,487	19,386	43.7%
PBIT Margins %						
Transmission	58.6%	60.4%	1.79%	58.7%	61.8%	3.19%
Consultancy	38.6%	52.4%	13.81%	45.3%	59.2%	13.97%
Telecom	27.4%	31.1%	3.71%	33.0%	29.9%	-3.09%
Total	57.5%	59.7%	2.17%	57.7%	61.2%	3.50%

Source: Company data, Citi Research.

3

Power Grid Corporation of India

Company description

PGCIL (61.42%-owned by the Government of India) is India's Central Transmission Utility (CTU) mandated to establish and operate regional and national grids to facilitate transfer of power within and across regions. It commenced operations in April 1992 and carries about 45% of India's generated electricity. At 31 March 2012, it had a transmission network of about 92,981 circuit kms with 150 substations, and system availability of above 99.94%. PGCIL also plays an active role in distribution sector reforms initiated by government. PGCIL has also diversified to provide broadband telecom services and consultancy for T&D projects in India and abroad.

Investment strategy

We rate PGCIL Buy to factor in (1) its scarcity value, as it is the only listed play on the regulated transmission business in India vis-a-vis plenty of generation companies to chose from, and (2) EPS CAGR of 17% over FY12-15E with average RoE of 16%. PGCIL plans Rs1000bn of capex during the XIth Five Year Plan (FY13-17). Under the regulatory regime, PGCIL's sales and earnings growth is largely driven by capex and capex that it capitalizes and brings into its gross block. The capex is incrementally funded through a 70:30 debt: equity mix. Capitalization again depends on commissioning transmission lines.

Valuation

DCF is normally preferred when valuing an electric utility company that has regulated earnings and cash flow streams. However, for a company like PGCIL, which we estimate will be FCF negative until at least FY12E and might continue to be FCF negative beyond FY12E depending on the scale of the capex it undertakes in the XIIth Plan (FY13E -FY17E), the DCF approach could either overestimate or underestimate the value of the company based on the terminal year cash-flow assumptions. The entire value would depend on the steady state case assumed when growth capex stops and the company does only maintenance capex and generates substantial amounts of cash. The DCF value would also be extremely sensitive to the maintenance capex assumption in the terminal year. We therefore believe P/BV valuation methodology is more appropriate. Our target price of Rs140 is set at 2.2x P/BV for Mar14E, a ~8% discount to the historical average P/BV of 2.4x since listing, given the sector's generic risks of coal shortage, falling merchant prices and deteriorating SEB finances.

Risks

Key downside risks to our target price include: 1) Creditworthiness of the State Power Utilities; 2) Changes in the regulatory environment; 3) Increased competition; and 4) Project-related risks. Key upside risks are: 1) Faster-than-expected project execution leading to earlier capitalization of capex; 2) Higher-than-expected short-term open access revenues due to a spurt in power trading, and 3) Higher-than-expected revenues and profitability in consulting and telecoms businesses.

Jaiprakash Power Ventures

Investment strategy

We have a Buy rating on JP Power Ventures. The company has an interesting and diversified (fuel wise and off-take wise) portfolio of projects, which includes 1700MW of operational capacity and 3,800MW of under-construction capacity. We expect an EPS CAGR of 65% over FY11-15E with RoE expanding from 8% in FY12 to 21% in FY15E.

Valuation

We value JP Power Ventures at Rs46 a share. The Indian power sector has seen a sea change over the last 4-5 years, moving from an era of: (1) assured RoE, where fuel cost was a pass through; (2) Coal India honored its coal linkages most of the time; (3) imported coal was a small quantum of India's requirement; (4) analysts and investors did not have to bother about merchant prices and fuel costs; and (5) though SEBs were making losses, they were not asking generators to back down generation to an era where: (1) case 1 and case 2 are becoming more common than assured RoE; (2) one is worried if Coal India will honor its coal linkage contracts; (3) imported coal is becoming increasing important; (4) analysts and investors have to bother about merchant prices and fuel costs; and (5) SEBs are asking generators to back down generation. This means one has to adapt valuation approaches to keep up with the sudden changes in operating outlook for companies. Though DCF using FCFE and cost of equity remains a robust approach for valuation, it prevents maneuverability in a fast-changing environment. We therefore use P/BV to value JP Power Ventures. We use a target P/BV of 1.6x Mar14E considering the company's EPS CAGR of 65% over FY12-15E with RoEs expanding from 8% to 21%.

Risks

Downside risks to our target price include: fuel supply risk, coal mining risk, execution risk, merchant tariff risks, hydrological risk, financial closure risk, dependence on promoter and promoter group companies, receivables risk, regulatory risk, R&R and land acquisition risk and lower-than-expected operating parameters.

Tata Power

5

Investment strategy

We rate Tata Power a Sell with a target price of Rs89. Over the years investors/analysts have extrapolated rising coal volumes, ASPs and depreciating rupee to build a bull case, ignoring likely losses in Mundra UMPP and possibility of some of the +ve coal drivers reversing. Mundra UMPP losses are a reality now (cannot be undone without tariff hikes not mandated in PPA), coal ASPs are declining and cost of production is increasing.

Our worst fears on Mundra UMPP are also coming true with the company taking an impairment of Rs18bn in FY12 based on upward revision to coal price projections and USDINR.

In order to support Mundra UMPP, management has committed to restructuring under which the company will transfer at least 75% of the ownership of the investments in the Indonesian coal companies to Mundra UMPP in FY12E. The company will also evaluate other alternative options to support Mundra UMPP. The two possible outcomes of the same are (1) some amount of tax arbitrage which is a positive, and (2) more accounting complexity in an already complex accounting company, which is a negative.

Valuation

Our Rs89 target price is based on a sum-of-the-parts approach: 1) The parent business is valued using DCF as of Dec12E, using a WACC of 12.3% (risk free rate of 8.5%, market risk premium of 6%, beta of 1.06, D/E of 67%); 2) Tata Power's 51% stake in NDPL is valued at 0.75x Mar12 P/BV; 3) Tata Power's stake in Powerlinks is valued at 2.5x FY12 P/BV; 4) Holdings in Tata Teleservices (Maharashtra) and VSNL are valued at a 20% discount to the market prices; 5) Stake in Tata Teleservices is valued at a 45% discount to the NTT Docomo valuations; 6) Mundra UMPP using FCFE and Cost of Equity = 13%; 7) The Maithon project is valued like the Mundra UMPP using a CoE=13%; and 8) 30% stake in KPC and Arutmin coal mines at FCF and WACC = 12%.

Risks

Key upside risks that could drive the shares above our target price include: 1) Positive judgment on the MERC order and standby charges case vs. R--Infra could positively impact investor sentiment but have no positive bearing on Tata Power's financials, on our estimates; 2) Tata Power exiting its telecom holdings at a significant premium to their current market value; 3) Significant progress on pipeline of 6.2GW of projects beats expectations and 4) New UMPP win.

Adani Power

Investment strategy

We rate Adani Power Sell. The business model on paper has not panned out in reality. The key spoilers have been (1) slower ramp up (2) higher auxiliary consumption (3) lower merchant sales (4) higher fuel costs (5) higher O&M costs (6) duty on Mundra sales and (7) significant cost over-runs. Post 3 years of operation, the company is staring at an overleveraged balance sheet, PPAs with limited maneuverability, coal shortages and higher fuel costs.

Valuation

6

The Indian power sector has seen a sea-change over the last 4-5 years from an era of: (1) assured RoE where fuel cost was a pass-through; (2) Coal India honored its coal linkages most of the time; (3) imported coal was a small quantum of India's requirement; (4) analysts/ investors did not have to bother about merchant prices/fuel costs; and (5) though SEBs were making losses, they were not asking generators to back down generation to an era where (1) case 1 and case 2 are becoming more common than assured RoE; (2) concerns are rising as to whether Coal India will honor its coal linkage contracts; (3) imported coal is becoming increasingly important; (4) analysts/investors have to bother about merchant prices/fuel costs; and (5) SEBs are asking generators to back down generation. This means valuation approaches have to be adapted to keep up with the sudden

changes in operating outlook for companies. As a consequence, we now use a pure P/BV multiple set on Dec13E at 1.2x. Our target multiple is well supported by average RoE of 6.4% over FY13-15E.

Risks


Upside risks that could cause the stock to trade above our target price include: 1) Better-than-expected operating parameters; 2) Faster-than-expected execution; 3) Higher-than-expected merchant tariffs; 4) Pass through of costs in low priced PPAs; 5) Significant fall in international coal prices; 6) Allocation of coal mine for Tiroda.

Appendix A-1


Analyst Certification


The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES



7





Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Power Grid Corporation of India, Adani Power, Tata Power.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from Power Grid Corporation of India.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Power Grid Corporation of India, Adani Power, Jaiprakash Power Ventures, Tata Power in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): Power Grid Corporation of India, Adani Power, Tata Power.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Power Grid Corporation of India, Adani Power, Tata Power.

9

Citi Research

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: Power Grid Corporation of India, Adani Power, Jaiprakash Power Ventures, Tata Power.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Research Ratings Distribution

•	12 Mc	nth Ratii	Relative Rating			
Data current as of 5 Oct 2012		Hold	Sell	Buy	Hold	Sell
Citi Research Global Fundamental Coverage	51%	38%	11%	7%	85%	7%
% of companies in each rating category that are investment banking clients	50%	47%	45%	59%	47%	50%

Guide to Citi Research Fundamental Research Investment Ratings:

Citi Research stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

Risk rating takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned. Investment Ratings: Citi Research investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect with the approval of Citi Research management not to assign a target price and, thus, not derive an ETR. Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and / or trading in the company's securities (e.g. trading suspension). As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. To satisfy regulatory requirements, we correspond Under Review and Neutral to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation. Relative three-month ratings: Citi Research may also assign a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the geographic and industry sector over a 3 month period. The relative call may highlight a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) will indicate the most and least preferred stocks in the universe of stocks under consideration, explaining the basis for this short-term view. This three-month view may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls correspond to a buy recommendation and least preferred calls correspond to a sell recommendation. Any stock not assigned to a most preferred or least preferred call is considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we correspond NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we do not consider NRR to be a recommendation.

Prior to October 8, 2011, the firm's stock recommendation system included a risk rating and an investment rating. **Risk ratings**, which took into account both price volatility and fundamental criteria, were: Low (L), Medium (M), High (H), and Speculative (S). **Investment Ratings** of Buy, Hold and Sell were a function of the Citi Research expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating. Additionally, analysts could have placed covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" were monitored daily by management and as practically possible, the analyst published a note re-establishing a rating and investment thesis. For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings were:Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and Latin America), investment ratings were:Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

10

Citigroup Global Markets India Private Limited

Venkatesh Balasubramaniam; Atul Tiwari, CFA; Deepal Delivala; Vaishnavi G

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 31 October 2012 04:00 PM on the issuer's primary market.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an of

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Research research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to Citi Research research reports.

Important disclosure regarding the relationship between the companies that are the subject of this Citi Research research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citivelocitv.com/cvr/eppublic/citi_research_disclosures.

This Citi Research research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of Citi Research. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11° andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in Chile through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in France by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong, Citibank

N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in Israel through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A, Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in Japan by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Pakistan by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan, AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the Philippines through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold//Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Spain by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the Republic of China through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public

information on such security or the financial products or any registered prospectus. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in Turkey through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the U.A.E, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocitv.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution. The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2012 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST

